Liver Heart Articles & Analysis
17 news found
Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue ...
ByCELLINK
P000912-LYSK1-A.0 Soft tissue homogenizing CK14 The CK14 kit is the perfect solution for soft tissue homogenization, like brain, liver, kidney, skin, plant leaves, mammalian cells and more. Compatible with Precellys Evolution Touch, Precellys 24 Touch and Minilys, the kit comes in different sizes, including 0.5mL, 2mL, 2mL Protein Safe or 7mL standard tubes. ...
The second, REVeRT (REconstitution Via mRNA Trans-splicing) technology platform, allows efficient reconstitution of large genes (>5Kb) in various tissues such as retina, brain, heart, liver, and skeletal muscle. The third, AAV Transactivation is a CRISPR-Cas–based AAV gene therapy platform that enables to regulate one or multiple genes in vivo. ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI (UK) Limited (“Kreos”). ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. ...
In combination with work continuing at the University of Miami, we believe that our ImmCelz® platform has enormous potential to improve outcomes for patients across multiple indications, including Stroke, Type I Diabetes, Heart Disease, Liver Disease, and Kidney Disease." Human iPSc's are genetically reprogrammed to differentiate into a wide array of human ...
We believe that our Immcelz® program has enormous potential to improve outcomes for patients across multiple indications, including stroke, Type I diabetes, heart disease, liver disease, and kidney disease." About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to ...
Upon successful approval to proceed with clinical trials for stroke, the Company anticipates accelerating additional therapies under the ImmCelz® umbrella, including for type I diabetes, heart disease, liver disease, and kidney disease. About Creative Medical Technology Holdings Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology ...
Spare parts for the people who need them: Lungs, livers, kidneys, hearts. It’s been nearly five years since Kamen announced the launch of BioFabUSA, a program of the Advanced Regenerative Manufacturing Institute to jump-start the large-scale production of synthetic human tissue. ...
As a small molecule, HST5040 has the ability to distribute to all affected tissues and thus has the potential to be active throughout the body, including the liver, kidneys, brain, heart and muscles. HST5040 is designed for convenient daily administration at home as a liquid formulation taken either orally or through a gastric feeding tube. ...
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
As a result of longer life expectancy and the incidence of major pathologies such as cancer and diabetes, the number of people waiting for an organ transplant is constantly increasing: at the end of 2016 in the EU member countries more than 142,000 patients were waiting for a kidney, liver, heart, lung, pancreatic or intestinal transplant (source: EDQM Council of ...
ByPoietis
MIROMESH is a biological mesh derived from perfusion decelluarized porcine liver, compressed and cut into a variety of sizes suited for hernia repair applications. MIRODERM is also derived from decellularized porcine liver and further processed for use in the management of wounds including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and ...
Since their initial discovery more than 50 years ago by James Till and Ernest McCulloch, adult stem cells have been found in many more tissues than initially anticipated, including brain, bone marrow, fat, peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithelium and testis. These cells could be used for patient-specific ...
Cochrane awoke to a shortness of breath that eventually landed him in an emergency room later that day. Fears of a potential heart attack were quickly dismissed and replaced by new concerns over a growth discovered on his lung. ...